



e project provided:

B.4 What opportunities for training and professional development are there

with this program that are not available elsewhere?

Under the guidance of a senior professional, members are under increased pressure


to meet the needs of the community. The program is designed to provide a high level of service to the community.

PRODUCTS

01/10/2010

PUBLICATIONS

11/11/2010 10:10:10 AM




D. PARTICIPANTS


WORKED ON THE PROJECT?

J. AYATA AND V. JUALSTAVEA

NAME	EMAIL	PHONE	ADDRESS	STATUS
NA				
WACOMMUNA				
User Name				
Y				
LOTEZ				
BARHO, PDR				
MD				
ETGI				
STAFF				
Y				
Presid				
Marie Elena				
JAK G.				
SHIBO				
MS				
MS				
Kund, I				
Raka				



D.2 PERSONNEL UPDATES  
D.2.a Level of Effort













25-2015/0731

2009/08/

New York Blood Center); Sara Lustigman (PI)

1 R01A1078314 03, NIH/NIAID (Sub-award from: Ne

uman onchocerciasis

The development of a recombinant vaccine against h

OTHER SUPPORT

ER J.

HOTEZ, PET

awarded:

New grants

Instituto Carlos Simbela Saubol 1/15/17 - 10/31/18  
Private Source 1/15/17 - 10/31/17

Grant ended:

Jan Government of South Carolina

CURRENT

EFFORT

1/15/17 - 10/31/18

The major goal of this project is to determine the early detection and  
prevalence of SARS-CoV-2 in the United States. The project will focus on  
diseases in Latin America, Central and South America - Otago disease.

Sponsor: National Institutes of Health

Title: RBD Recombinant D

The transmission of hookworms is a major public health problem in developing countries. The development of a vaccine to complement the Human Hookworm Vaccine now under development by the Sabin PDP.

2012-10-15 12:06:16  
Instituto Carlos Slim de la Salud 58873944  
Initiative for Anupoverly vaccine Development (Anagas)  
EFFORT  
BU. JAZZ (1-1)  
7/16/12  
Spor

OTHER SUPPORT BOTTAZZI MARIA ELENA

New agent's awarded

Instituto Carlos Slim de Salud 11/1/15 - 10/31/18

Private Source 11/1/15 - 10/31/18

NOVA

ACTIVE

EFFORT

Private Source

\$229,019

EFFORT

NOVA

\$33,000




1/1/15 - 12/31/17

**ACTIVE**







Pending Support

OVER AP

Change for Dr. Shibo Jiang and Lewis D. ...

**SHIBO JIANG**

**ACTIVE**

ED01-1000775-04 - U.S. Patent Office (D.O.)

E. IMPACT

E.1 WHAT IS THE IMPACT ON THE DEVELOPMENT OF HUMAN RESOURCES?

F. CHANGES

F.1 CHANGES IN APPROACH AND REASONS FOR CHANGE

None

None

Actual grant title: Dr. Huijie Chen and Dr. J. Tony Dong, PI's

Subjects

3.a. Human Subjects



1.1

Environmental Health & Safety

Biological & Chemical Safety Program  
Materials Management Building, 2412  
361 University Blvd. 111

March 14, 2018

Galveston, Texas 77559-1111 Galveston TX 77559-1111  
O 409.772.1781 F 409.772.8921

Dear Colleague:

*[The following text is extremely faint and largely illegible due to heavy noise and artifacts in the scan. It appears to be the beginning of a letter or report.]*



TERMS AND CONDITIONS OF USE AND PRIVACY POLICY

2013-01-01 10:05:05 AM

utmb select agent.pdf

5.2 RESPONSIBLE CONDUCT OF RESEARCH

Not Applicable


6. CONFIDENTIALITY OF DATA AND COMMENTS

Not Applicable

14. HUMAN SUBJECTS

6.4.a Does the project involve human subjects?

Yes







Biological & Chemical Safety Program  
Materials Management Building, 2.112  
301 University Blvd.  
Galveston, Texas 77556-1114

With respect to 40 CFR 119.600-11.11.11  
A 409.770.4704 E 409.770.6004

February 1, 2012


To Whom It May Concern:

The University of Texas Medical Branch at Galveston (UTMB) is a registered agent.

the Richard H. Sorenson Center for Disease Prevention, a registered entity with the U.S. M

Public Health Service, 2009-2010, and 2010-2011. UTMB, Galveston, Texas, U.S.A.

Department of Health and Human Services, U.S. Department of Health and Human Services, U.S. HHS





National Institutes of Health

Grant Number: CA141040-02 5R01CA141040-02

Principal Investigator(s):

Marta Elena Botazzi

SHIBO JIANG MD

Leanne Brooks Scott

Business Official

Business Official

Award e-mailed to: [bcmaward@bcm.edu](mailto:bcmaward@bcm.edu)

Budget Period: 05/01/2013 - 04/30/2014

05/01/2013 - 04/30/2017

Project Period: 05/01/2013 - 04/30/2017



U.S. Dollars)

Award Calculation (U.S.

\$955,528

Federal Direct Costs

\$120,702

Federal E&A Costs

\$1,085,321


Federal Share

\$1,085,321

Federal Share

TOTAL FEDERAL AWARD AMOUNT

\$1,085,321



Select Agents if the final registration certificate is denied. \_\_\_\_\_



Budget	Year 2	Year 3	Year 4	Year 5
--------	--------	--------	--------	--------

TOTAL FEDERAL	\$65,500	\$600,000	\$700,000	\$700,000
---------------	----------	-----------	-----------	-----------

DC

TOTAL FEDERAL	\$109,793	\$224,473	\$282,031	\$282,031
---------------	-----------	-----------	-----------	-----------


F&A

TOTAL COST	\$1,095,224	\$1,194,360	\$1,414,062	\$1,414,062
------------	-------------	-------------	-------------	-------------

Initiation and	Year 2	Year 3	Year 4	Year 5	Year 6
----------------	--------	--------	--------	--------	--------

Administrative

Costs





...yeast expression revealed that at least one of our constructs (rBBD193-N1) shows great promise for

are encouraging. We also observed that the protein levels of the mutant were not significantly different from the wild type. These results are encouraging and suggest that the mutant is a viable alternative to the wild type. However, we also observed that the mutant was not as stable as the wild type. Figure 2. Western blot analysis of the mutant and wild type protein levels. The blot was probed with a conformational epitope specific mAb 33G4 (Figure 2). These data suggest that the mutant is a viable alternative to the wild type. However, we also observed that the mutant was not as stable as the wild type. Figure 2. Western blot analysis of the mutant and wild type protein levels. The blot was probed with a conformational epitope specific mAb 33G4 (Figure 2). These data suggest that the mutant is a viable alternative to the wild type. However, we also observed that the mutant was not as stable as the wild type.

PRODUCTS C.1 PUBLICATIONS

publications or other research during the reporting period resulting directly from this award?

Yes  No

Public Access Compliance

P.I. Readman to developing a recombinant coronavirus S protein receptor binding

2019-2020

D. PARTICIPANTS

NA

Y JIANG.

PHD.MD PD/PI

SHIBO,

ao.

Ph.D

Postdoctora

NA

Xiang

Scor ar

Postdoctora

Y.A. Zhai

MD Zhai

Investigator

Elissam

Seid, Chris.-

Ph.D

Staff  
scientist  
(Doctors)

NA

ID	Name of person or entity	Title	Address	City	State	Zip	Phone	Fax	E-mail	Foreign	Origin	Affiliation	a	b	c	d	e	f	g
----	--------------------------	-------	---------	------	-------	-----	-------	-----	--------	---------	--------	-------------	---	---	---	---	---	---	---

S/K - Senior/Key

SS - Supplement Support

